IFNG and non-small cell lung carcinoma: A more recent phase II clinical trial evaluated the use of IFN-γ-Dex, Dex derived from IFN-γ-stimulated mature DC, as a maintenance immunotherapy after the use of first line chemotherapy in advanced NSCLC patients (117).